Merit Medical Systems Inc 8-K Filing
Ticker: MMSI · Form: 8-K · Filed: Nov 3, 2025 · CIK: 856982
| Field | Detail |
|---|---|
| Company | Merit Medical Systems Inc (MMSI) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Merit Medical Systems Inc (ticker: MMSI) to the SEC on Nov 3, 2025.
How long is this filing?
Merit Medical Systems Inc's 8-K filing is 4 pages with approximately 1,105 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,105 words · 4 min read · ~4 pages · Grade level 14 · Accepted 2025-11-03 17:24:14
Filing Documents
- mmsi-20251103x8k.htm (8-K) — 51KB
- mmsi-20251103x8k001.jpg (GRAPHIC) — 11KB
- 0000856982-25-000058.txt ( ) — 189KB
- mmsi-20251103.xsd (EX-101.SCH) — 3KB
- mmsi-20251103_lab.xml (EX-101.LAB) — 15KB
- mmsi-20251103_pre.xml (EX-101.PRE) — 9KB
- mmsi-20251103x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 17, 2025, Merit Medical Systems, Inc. ("Merit") filed a Current Report on Form 8-K and related press release announcing it signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX Medical, Inc., to acquire the C2 CryoBalloon device and related technology (the "C2 CryoBalloon.Acquisition"). On November 3, 2025, Merit closed the C2 CryoBalloon Acquisition. The information contained in this Item 7.01 of this Current Report and in the attached Exhibit 99.1 is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act"). CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The information included in this Current Report contains forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and Section 27A of the Securities Act. In some cases, forward-looking statements can be identified by the use of terminology such as "anticipate," "believe," "continue," "estimate," "expect," "forecast," "intend," "may," "might," "plan," "potential," "project," "will," "would," "seek," "should," "could," "can," "predict," "potential," "continue," "objective" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits EXHIBIT NUMBER DESCRIPTION 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MERIT MEDICAL SYSTEMS, INC. Date: November 3, 2025 By: /s/ Brian G. Lloyd Brian G. Lloyd Chief Legal Officer and Corporate Secretary 4